- LIVE QUOTES
- LEARN
- HELP
More from Webull
Our Partners
Wall Street JournalEN
A
ADCT
Adc Therapeutics Sa
1.42
-0.04-2.74%After Hours: 1.400 -0.02 -1.40%16:39 04/29 EDT
OPEN/PREV CLOSE1.430/1.460
TODAY RANGE1.390-1.460
VOL189.09K
MARKET CAP140.83M
52 WEEK RANGE1.050-5.17
AVG VOL (3M)378.41K
% TURNOVER0.19%
TURNOVER--
P/E (TTM)-0.8741
% RANGE4.79%
EPS(TTM)-1.6246
P/E(FORWARD)-0.9161
P/B0.5844
BVPS2.430
DIVIDEND--
P/S91.03
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP102.05M
SHARES OUTSTANDING99.18M
NEXT EARNINGS05/05-05/20
FREE FLOAT71.87M
LOT SIZE1
EX-DIV DATE--
News
Press Releases
Financial Reports
Profile
TipRanks·04/05 01:48
RBC Capital Keeps Their Buy Rating on ADC Therapeutics (ADCT)
Simply Wall St·04/04 10:43
ADC Therapeutics SA's (NYSE:ADCT) 31% Dip In Price Shows Sentiment Is Matching Revenues
PR Newswire·04/01 20:05
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
Dow Jones·03/31 14:02
ADC Therapeutics Is Maintained at Buy by Guggenheim
Dow Jones·03/31 14:02
ADC Therapeutics Price Target Cut to $7.00/Share From $10.00 by Guggenheim
Benzinga·03/31 13:54
Guggenheim Maintains Buy on ADC Therapeutics, Lowers Price Target to $7
TipRanks·03/31 12:55
ADC Therapeutics: Strong Financials and Promising Trials Support Buy Rating
TipRanks·03/31 11:00
ADC Therapeutics price target lowered to $7 from $10 at Guggenheim
TipRanks·03/29 00:03
ADC Therapeutics Earnings Call: Optimism Amid Challenges
Simply Wall St·03/28 11:21
ADC Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag
TipRanks·03/28 10:39
ADC Therapeutics (ADCT) Gets a Buy from RBC Capital
TipRanks·03/28 03:53
ADC Therapeutics Reports Strong 2024 Financials and Trial Progress
Same Industry
Name/Symbol
Change%
Price